Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...
The Globe and Mail4h
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways ...
ETF Daily News21d
Skye Bioscience (NASDAQ:SKYE) Shares Up 5.3% – Here’s Why
Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report) shares were up 5.3% during trading on Wednesday .The company traded as high as $5.20 and last traded at $5.20. Approximately 168,072 shares ...
Morningstar12d
Skye Bioscience to Announce Third Quarter 2024 Results
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for ...
Yahoo Finance16d
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for ...
Nasdaq20d
Skye Bioscience Approves Incentive Plan Amendments and Leadership Changes
Skye Bioscience ( (SKYE)) just unveiled an announcement. Skye Bioscience, Inc. held a special meeting where stockholders approved an amendment to increase the shares available under the 2014 ...
The Globe and Mail12d
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 ...
Wall Street Journal1mon
Skye Bioscience Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Mena FN13d
Skye Bioscience To Announce Third Quarter 2024 Results
(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical ...
Mena FN16d
Skye Bioscience Names Independent Director Paul Grayson As Chairman Of The Board
(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical ...
manilatimes13d
Skye Bioscience to Announce Third Quarter 2024 Results
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic ...